ImmunityBio Inc

NASDAQ:IBRX   3:59:51 PM EDT
8.68
-0.49 (-5.34%)
Products, Regulatory

Immunitybio Announces 12-Month Overall Survival Probability Of 83% In Nci-Led Phase 1 Study Of Multi-Targeted Had5 Immunotherapy Vaccine

Published: 03/29/2021 14:06 GMT
ImmunityBio Inc (IBRX) - Immunitybio Announces 12-month Overall Survival Probability of 83% in Nci-led Phase 1 Study of Multi-targeted Had5 Immunotherapy Vaccine in Patients With Advanced Metastatic Prostate Cancer.
Immunitybio Inc - Second-generation Human Adenovirus (had5) Targeting Multiple Tumor Associated Antigens Demonstrated Safety.
Immunitybio Inc - Preliminary Signals of Activity Include a 60% Disease Control Rate of at Least Six Months.
Immunitybio Inc - Preliminary Signals of Activity Include 12-month Probability of Survival of 83% With Median Survival Not Yet Reached.